-
EP2817302
European procedure
Extract from the Register of European Patents
EP About this file: EP2817302
| EP2817302 - 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.11.2016 Database last updated on 12.07.2024 | Most recent event Tooltip | 24.07.2020 | Change - lapse in a contracting state State(s) deleted from list of lapses: MK | published on 26.08.2020 [2020/35] | Applicant(s) | For all designated states Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Viale Amelia, 70 00181 Roma / IT | [2015/01] | Inventor(s) | 01 /
ALISI, Maria Alessandra Via Nemorense 188 I-00199 Roma / IT | 02 /
CAZZOLLA, Nicola Via Abetonia 20/L I-00041 Albano Laziale (Roma) / IT | 03 /
DRAGONE, Patrizia Via Castelchiodato 12 I-00131 Roma / IT | 04 /
FURLOTTI, Guido Via Ferdinando Palasciano 96 I-00151 Roma / IT | 05 /
MAUGERI, Caterina Via Val Seriana 10 I-00141 Roma / IT | 06 /
OMBRATO, Rosella Via Abigaille Zanetta, 68 00143 Roma / IT | 07 /
MANCINI, Francesca Via Genova 15 I-00048 Nettuno (Roma) / IT | [2016/01] |
| Former [2015/01] | 01 /
ALISI, Maria Alessandra Via Nemorense 188 I-00199 Roma / IT | ||
| 02 /
CAZZOLLA, Nicola Via Abetonia 20/L I-00041 Albano Laziale (Roma) / IT | |||
| 03 /
DRAGONE, Patrizia Via Castelchiodato 12 I-00131 Roma / IT | |||
| 04 /
FURLOTTI, Guido Via Ferdinando Palasciano 96 I-00151 Roma / IT | |||
| 05 /
MAUGERI, Caterina Via Val Seriana 10 I-00141 Roma / IT | |||
| 06 /
OMBRATO, Rosella Via Giuseppe di Vittorio, 27 87040 San Lorenzo Del Vallo (CS) / IT | |||
| 07 /
MANCINI, Francesca Via Genova 15 I-00048 Nettuno (Roma) / IT | Representative(s) | Allaix, Roberto, et al Marchi & Partners S.r.l. Via Vittor Pisani, 13 20124 Milano / IT | [2016/01] |
| Former [2015/01] | Allaix, Roberto, et al Marchi & Partners S.r.l. Via Pirelli, 19 20124 Milano / IT | Application number, filing date | 13704910.2 | 07.02.2013 | [2016/01] | WO2013EP52400 | Priority number, date | EP20120156292 | 21.02.2012 Original published format: EP 12156292 | [2015/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013124158 | Date: | 29.08.2013 | Language: | EN | [2013/35] | Type: | A1 Application with search report | No.: | EP2817302 | Date: | 31.12.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.08.2013 takes the place of the publication of the European patent application. | [2015/01] | Type: | B1 Patent specification | No.: | EP2817302 | Date: | 30.12.2015 | Language: | EN | [2015/53] | Search report(s) | International search report - published on: | EP | 29.08.2013 | Classification | IPC: | C07D401/12, C07D401/14, A61K31/454, A61K31/4545, A61P3/00, A61P25/00, A61P29/00, A61P35/00, C07D405/14, C07D413/14 | [2015/31] | CPC: |
C07D401/12 (EP,CN,US);
A61K31/454 (EP,US);
A61K31/4545 (EP,US);
A61K31/506 (EP,US);
A61P1/04 (EP);
A61P1/18 (EP);
A61P13/08 (EP);
A61P15/00 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/08 (EP);
A61P25/14 (EP);
A61P25/16 (EP);
A61P25/18 (EP);
A61P25/24 (EP);
A61P25/28 (EP);
A61P25/30 (EP);
A61P25/36 (EP);
A61P29/00 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/08 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
|
| Former IPC [2015/01] | C07D401/12, C07D401/14, A61K31/454, A61K31/4545, A61P3/00, A61P25/00, A61P29/00, A61P35/00, C07D405/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/01] | Extension states | BA | 09.09.2014 | ME | 09.09.2014 | Title | German: | 1H-INDAZOL-3-CARBOXAMID-VERBINDUNGEN ALS GLYCOGEN-SYNTHASE-KINASE 3-BETA INHIBITOREN | [2015/31] | English: | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | [2015/01] | French: | COMPOSÉS DE 1H-INDAZOLE-3-CARBOXAMIDE EN TANT QU'INHIBITEURS DE LA GLYCOGÈNE SYNTHASE KINASE-3 BÊTA | [2015/31] |
| Former [2015/01] | 1H-INDAZOL-3-CARBOXAMID-VERBINDUNGEN ALS GLYCOGEN-SYNTHASE-KINASE-3-BETAINHIBITOREN | ||
| Former [2015/01] | COMPOSÉS 1H-INDAZOLE-3-CARBOXAMIDE EN TANT QU'INHIBITEURS DE LA GLYCOGÈNE SYNTHASE KINASE 3 BÊTA | Entry into regional phase | 09.09.2014 | National basic fee paid | 09.09.2014 | Designation fee(s) paid | 09.09.2014 | Examination fee paid | Examination procedure | 09.09.2014 | Examination requested [2015/01] | 03.04.2015 | Amendment by applicant (claims and/or description) | 17.07.2015 | Communication of intention to grant the patent | 22.10.2015 | Fee for grant paid | 22.10.2015 | Fee for publishing/printing paid | 22.10.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 17.07.2015 | Opposition(s) | 03.10.2016 | No opposition filed within time limit [2016/49] | Fees paid | Renewal fee | 20.02.2015 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2020/35] |
| Former [2018/32] | MK | 30.12.2015 | |
| Former [2016/27] | deleted | ||
| Former [2016/25] | LV | 30.12.2015 | Cited in | International search | [AD]WO2004074275 (ACRAF [IT], et al) [AD] 1-23 * claims 1-35 ** page 1, lines 5-7 *; | [A]WO2008154241 (ABBOTT LAB [US], et al) [A] 1-23 * page 1, lines 4-7 * * claims 1-156 *; | [A]US2011112161 (BOLIN DAVID ROBERT [US], et al) [A] 1-23 * page 1, paragraph 2 * * claims 1-16 * | by applicant | WO9410174 | WO2004014864 | WO2004074275 | WO2004101548 | WO2010109005 | - NEUROSCIENCE LETTERS, (2004), vol. 368, pages 123 - 126 | - GRIMES; JOPE, PROGRESS IN NEUROBIOLOGY, (2001), vol. 65, pages 391 - 426 | - GEETHA, BRITISH JOURNAL PHARMACOLOGY, (2009), vol. 156, pages 885 - 898 | - EMBI ET AL., EUR J BIOCHEM, (1980), vol. 107, pages 519 - 527 | - COHEN ET AL., FEBS LETT., (1997), vol. 410, pages 3 - 10 | - DOKKEN ET AL., AM J. PHYSIOL. ENDOCRINOL. METAB., (2005), vol. 288, pages E1188 - E1194 | - RING DB, DIABETES, (2003), vol. 52, pages 588 - 595 | - HANGER ET AL., NEUROSCI. LETT., (1992), vol. 147, pages 58 - 62 | - MAZANETZ; FISCHER, NAT REV DRUG DISCOV., (2007), vol. 6, pages 464 - 479 | - HONG; LEE, J. BIOL. CHEM., (1997), vol. 272, pages 19547 - 19553 | - CEDAZO-MINGUEZ ET AL., JOURNAL OF NEUROCHEMISTRY, (2003), vol. 87, pages 1152 - 1164 | - HERNANDEZ; AVILA, FEBS LETTERS, (2008), vol. 582, pages 3848 - 3854 | - DUKA T. ET AL., THE FASEB JOURNAL, (2009), vol. 23, pages 2820 - 2830 | - MEIJER L. ET AL., TRENDS PHARM SCI, (2004), vol. 25, pages 471 - 480 | - CALDER6 J. ET AL., "Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord", NEUROSCIENCE, (20100217), vol. 165, no. 4, pages 1353 - 69 | - LEGER B. ET AL., "Atrogin-1, MuRFI, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients", MUSCLE NERVE, (200907), vol. 40, no. 1, pages 69 - 78 | - GALIMBERTI D. ET AL., "GSK3? genetic variability in patients with Multiple Sclerosis", NEUROSCI LETT., (20110615), vol. 497, no. 1, doi:doi:10.1016/j.neulet.2011.04.024, pages 46 - 8, XP028212715 DOI: http://dx.doi.org/10.1016/j.neulet.2011.04.024 | - JOPE; ROH, CURR. DRUG TARGETS, (2006), vol. 7, pages 1421 - 1434 | - CHEN ET AL., J. NEUROCHEM., (1999), vol. 72, pages 1327 - 1330 | - KLEIN; MELTON, PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 8455 - 8459 | - GOULD, EXPERT. OPIN. THER. TARGETS, (2006), vol. 10, pages 377 - 392 | - EMAMIAN ET AL., NAT GENET, (2004), vol. 36, pages 131 - 137 | - JIA LUO, CANCER LETTERS, (2009), vol. 273, pages 194 - 200 | - RINNAB ET AL., NEOPLASIA, (2008), vol. 10, pages 624 - 633 | - GARCEA ET AL., CURRENT CANCER DRUG TARGETS, (2007), vol. 7, pages 209 - 215 | - QI CAO ET AL., CELL, (2006), vol. 16, pages 671 - 677 | - GHOSH ET AL., CLIN CANCER RES, (2005), vol. 11, pages 4580 - 4588 | - BIRCH ET AL., CANCER CELL, (2010), vol. 17, pages 529 - 531 | - G. KLAMER ET AL., CURRENT MEDICINAL CHEMISTRY, (2010), vol. 17, no. 26, pages 2873 - 2281 | - WANG ET AL., CYTOKINE, (2010), vol. 53, pages 130 - 140 | - MILLER JS ET AL., "Cocaine-induced hyperactivity and sensitization are dependent on GSK3", NEUROPHARMACOLOGY, (20090327), vol. 56, no. 8, doi:doi:10.1016/j.neuropharm.2009.03.006, pages 1116 - 23, XP026132938 DOI: http://dx.doi.org/10.1016/j.neuropharm.2009.03.006 | - LOHI H ET AL., HUM MOL GENET., (20050915), vol. 14, no. 18, pages 2727 - 36 | - PURI R ET AL., J BIOL CHEM., (20090821), vol. 284, no. 34, pages 22657 - 63 | - MAZZARDO-MARTINS L. ET AL., "Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action", NEUROSCIENCE, (20121213), page 226 | - S. PHUKAN ET AL., BRITISH JOURNAL OF PHARMACOLOGY, (2010), vol. 160, pages 1 - 19 | - MEIJER ET AL., CHEM. BIOL., (2003), vol. 10, pages 1255 - 1266 |